Search

Peptide therapeutics are one of the fastest-growing drug classes—but traditional synthesis methods often slow down innovation due to high costs, lengthy timelines, and purification bottlenecks.

Since its inception, ViroFend has focused on building an organization capable of translating a highly complex biomedical technology into the clinical setting, based on internationally leading

EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC, including sample size

Klinea Biotech & Pharma Engineering, together with professionals from the hospital sector, has analysed the main challenges that will shape the future of advanced therapies (ATMPs).

During the study period, an average of 14,6693 people died annually from acute myocardial infarction in Spain, with approximately 19% of these deaths occurring during working age.

Advanced therapies offer new therapeutic options for complex diseases and also represent a strategic asset due to their contribution to knowledge, employment, and technological innovation.

Key combination for the treatment of Small Cell Lung Cancer.

The sixth edition, organized by AseBio and the Salamanca City Council, will take place on April 21 at the Castilla y León Conference and Exhibition Centre.

The results will provide essential data for field monitoring, soil management, and production improvement.

Nostrum Biodiscovery marks ten years of growth and scientific innovation, celebrating its global presence and a portfolio of technologies designed to accelerate drug discovery.

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events